Akira Shimizu

Akira Shimizu

Auto-generated profile, based on publicly available information

Akira Shimizu

Departments of Chemistry and of Chemical and Systems Biology, Stanford University, Stanford, CA, 94305, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 October 2017 in Science
Verified
Journal Article
Closed access
PDF file
PWPaul A. Wender
Paul A. Wender
CHClayton T. Hardman
Clayton T. Hardman
SHStephen Ho
Stephen Ho
MJMatthew S. Jeffreys
Matthew S. Jeffreys
JMJana K. Maclaren
Jana K. Maclaren
MSMatthew C. Stevens
Matthew C. Stevens
A gram-scale route to bryostatin: Scientists once accumulated 14 tons of the red, bushy, tufted sea creature Bugula neritina to extract 18 grams of bryostatin 1. The macrocyclic organic compound is under study for treatment of HIV, cancer, and Alzheimer's disease but has proven frustratingly scarce. Wender et al. report a 29-step chemical synthesis of bryostatin 1 that proceeds in 4.8% overall yield and provides gram quantities of the compound (see the Perspective by Lanman). Intermediates along the pathway can be straightforwardly modified to produce analogs, two of which were prepared en route and studied in vitro. Science , this issue p. 218 ; see also p. 166

21 September 2017 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
MMMatthew D. Marsden
Matthew D. Marsden
BLBrian A. Loy
Brian A. Loy
XWXiaomeng Wu
Xiaomeng Wu
Christina M. RamirezChristina M. Ramirez
Christina M. Ramirez
ASAdam J. Schrier
Adam J. Schrier
JZJerome A. Zack
Jerome A. Zack
The ability of HIV to establish a long-lived latent infection within resting CD4+ T cells leads to persistence and episodic resupply of the virus in patients treated with antiretroviral therapy (ART), thereby preventing eradication of the disease. Protein kinase C (PKC) modulators such as bryostatin 1 can activate these latently infected cells, potentially leading to their elimination by virus-mediated cytopathic effects, the host’s immune response and/or therapeutic strategies targeting cells actively expressing virus. While research in this area has focused heavily on naturally-occurring PKC modulators, their study has been hampered by their limited and variable availability, and equally significantly by sub-optimal activity and in vivo tolerability. Here we show that a designed, synthetically-accessible analog of bryostatin 1 is better-tolerated in vivo when compared with the naturally-occurring product and potently induces HIV expression from latency in humanized BLT mice, a proven and important model for studying HIV persistence and pathogenesis in vivo. Importantly, this induction of virus expression causes some of the newly HIV-expressing cells to die. Thus, designed, synthetically-accessible, tunable, and efficacious bryostatin analogs can mediate both a “kick” and “kill” response in latently-infected cells and exhibit improved tolerability, therefore showing unique promise as clinical adjuvants for HIV eradication. HIV can persist for many years in a latent (non-expressing) state in individuals treated with antiretroviral therapy, and these latently-infected cells represent a major barrier to curing HIV infection. One potential approach to eliminating the reservoir cells is to induce them to express viral proteins while maintaining antiretroviral therapy, allowing these cells to be killed by the virus or the immune response. However, this approach has been hampered by a lack of compounds that can safely and effectively reverse HIV from latency in a living organism. Here we show that a designed, synthetic protein kinase C modulating compound is better-tolerated than the naturally-occurring product (bryostatin 1) in mice and potently induces HIV expression from latency in a mouse model containing a human immune system. Importantly, this induction of virus expression causes some of the newly HIV-expressing cells to die. Hence, this compound shows unique promise as a component of the so-called “kick and kill” approach for HIV eradication.

20 April 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
CHClayton Hardman
Clayton Hardman
SHStephen Ho
Stephen Ho
ASAkira Shimizu
Akira Shimizu
QLQuang Luu-Nguyen
Quang Luu-Nguyen
JSJack L. Sloane
Jack L. Sloane
PWPaul A. Wender
Paul A. Wender
Bryostatin 1 is a marine natural product under investigation for HIV/AIDS eradication, the treatment of neurological disorders, and enhanced CAR T/NK cell immunotherapy. Despite its promising activity, bryostatin 1 is neither evolved nor optimized for the treatment of human disease. Here we report the design, synthesis, and biological evaluation of several close-in analogs of bryostatin 1. Using a function-oriented synthesis approach, we synthesize a series of bryostatin analogs designed to maintain affinity for bryostatin’s target protein kinase C (PKC) while enabling exploration of their divergent biological functions. Our late-stage diversification strategy provides efficient access to a library of bryostatin analogs, which per our design retain affinity for PKC but exhibit variable PKC translocation kinetics. We further demonstrate that select analogs potently increase cell surface expression of CD22, a promising CAR T cell target for the treatment of leukemias, highlighting the clinical potential of bryostatin analogs for enhancing targeted immunotherapies.